a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Daver, Naval
Assi, Rita
Garcia-Manero, Guillermo
Ravandi, Farhad
Borthakur, Gautam
Jabbour, Elias J.
DiNardo, Courtney D.
Kadia, Tapan
Ning, Jing
Gonzalez, Graciela Nogueras
Pierce, Sherry
Kelly, Mary
Zhang, Weiguo
Gombos, Dan
Kornblau, Steven
Konopleva, Marina
Cortes, Jorge E.
Kantarjian, Hagop M.
Andreeff, Michael
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1344
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
    Daver, Naval
    Assi, Rita
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Jabbour, Elias
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Ning, Jing
    Nogueras-Gonzalez, Graciela
    Pierce, Sherry
    Gombos, Dan
    Komblau, Steven
    Konopleva, Marina
    Kelly, Mary
    Borthakur, Gautam
    Zhang, Weiguo
    Cortes, Jorge
    Kantarjian, Hagop
    Andreeffl, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S7 - S8
  • [2] Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
    Daver, Naval G.
    Assi, Rita
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Ravandi, Farhad
    Konopleva, Marina Y.
    Kadia, Tapan M.
    Borthakur, Gautam
    Jabbour, Elias J.
    DiNardo, Courtney D.
    Velasquez, Michelle
    Kelly, Mary
    Ning, Jing
    Gonzalez, Graciela M. Nogueras
    Pierce, Sherry A.
    Gombos, Dan
    Estrov, Zeev E.
    Kornblau, Steven M.
    Zhang, Weiguo
    Andreeff, Michael
    BLOOD, 2018, 132
  • [3] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy
    Ong, Faustine
    Short, Nicholas
    Daver, Naval
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Yilmaz, Musa
    Alvarado, Yesid
    Vaughan, Kenneth
    Pierce, Sherry A.
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    BLOOD, 2022, 140 : 9029 - 9031
  • [4] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
    Briski, Robert
    Short, Nicholas J.
    Daver, Naval
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Yilmaz, Musa
    Valero, Yesid Alvarado
    Vaughan, Kenneth
    Pierce, Sherry
    Montalbano, Kathryn
    Mullin, Jillian
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    BLOOD, 2023, 142
  • [5] Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations
    Randhawa, Jasleen K.
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Thompson, Philip Alastair
    Konopleva, Maria
    Daver, Naval
    Pemmaraju, Naveen
    Jabbour, Elias
    Kadia, Tapan M.
    Estrov, Zeev
    Ramachandran, Abhijit
    Paradela, Jamil
    Andreef, Michael
    Levis, Mark
    Ravandi, Farhad
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [6] Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia
    Wang, Eunice S.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 105 - 112
  • [7] First in Human (FIH) FLT3 and SYK Inhibitor HM43239 Shows Single Agent Activity in Patients (pts) with Relapsed or Refractory (R/R) FLT3 Mutated and Wild-Type Acute Myeloid Leukemia (AML)
    Daver, Naval
    Lee, Kyoo Hyung
    Jung, Chul Won
    Yoon, Sung-Soo
    Arellano, Martha L.
    Yoon, Jiyeon
    Lee, Nora
    Kim, Hyunjin
    Lee, Jaeyeon
    Jonas, Brian A.
    Baek, Seungjae
    BLOOD, 2021, 138
  • [8] Phase II study of cladribine, idarubicin, cytarabine (CLIA) plus gilteritinib in patients (pts) with FLT3 mutated acute myeloid leukemia (AML).
    Abuasab, Tareq
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Bravo, Guillermo Montalban
    Valero, Yesid Alvarado
    Daver, Naval Guastad
    Yilmaz, Musa
    Pemmaraju, Naveen
    Chien, Kelly Sharon
    Kornblau, Steven Mitchell
    Burger, Jan Andreas
    Jain, Nitin
    Islam, Rabiul
    Dinardo, Courtney Denton
    Borthakur, Gautam
    Jabbour, Elias
    Ravandi, Farhad
    Kadia, Tapan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia
    Fathi, Amir Tahmasb
    Arevalo, Mabel
    Gutierrez, Sonia
    Molero, Antonieta
    Sacilotto, Natalia
    Limon, Ana E.
    Faller, Douglas V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Daver, Naval
    Boddu, Prajwal
    Ravandi, Farhad
    Jabbour, Elias
    Borthakur, Gautam
    DiNardo, Courtney
    Konopleva, Marina
    Pemmaraju, Naveen
    Kadia, Tapan
    Jain, Nitin
    Pierce, Sherry
    Hussain, Nawar
    Ning, Jing
    Nogueras-Gonzalez, Graciela
    Basu, Sreyashi
    Cortes, Jorge
    Sharma, Padmanee
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S6 - S7
12345